{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:13:43Z","timestamp":1761621223082},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Internal Grant Agency of Ministry of Health, Czech Republic"},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education, Youth and Sports","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.chroma.2015.07.033","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T20:00:26Z","timestamp":1436817626000},"page":"173-181","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Detailed study of imatinib metabolization using high-resolution mass spectrometry"],"prefix":"10.1016","volume":"1409","author":[{"given":"David","family":"Friedeck\u00fd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Mi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Hrd\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"\u0160irok\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chroma.2015.07.033_bib0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.chroma.2015.07.033_bib0095","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.leukres.2010.07.014","article-title":"Relationship of serum imatinib trough level and response in CML patients: Long term follow-up","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.chroma.2015.07.033_bib0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.chroma.2015.07.033_bib0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12185-009-0263-z","article-title":"Long-term efficacy of imatinib in a practical settings is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group","volume":"89","author":"Sakai","year":"2009","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.chroma.2015.07.033_bib0110","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s12185-010-0576-y","volume":"91","author":"Faber","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.chroma.2015.07.033_bib0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","article-title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","volume":"63","author":"Menon-Andersen","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.chroma.2015.07.033_bib0120","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.chroma.2015.07.033_bib0125","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.chroma.2015.07.033_bib0130","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","article-title":"Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory aktivity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study","volume":"101","author":"Ishikawa","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.chroma.2015.07.033_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00216-008-1962-7","article-title":"High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites","volume":"391","author":"Holcapek","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.chroma.2015.07.033_bib0140","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.chroma.2015.07.033_bib0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0006-291X(88)80729-0","article-title":"Bioactivation of thenarcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl\/bufI)","volume":"152","author":"Dayer","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.chroma.2015.07.033_bib0150","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.chroma.2015.07.033_bib0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jms.1002","article-title":"Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers","volume":"41","author":"Marull","year":"2006","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.chroma.2015.07.033_bib0160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jms.1369","article-title":"Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry","volume":"43","author":"Rochat","year":"2008","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.chroma.2015.07.033_bib0165","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/rcm.4023","article-title":"Characterization of imatinib metabolites in rat and human liver microsomes: differentiation of hydroxylation from N-oxidation by liquid chromatography\/atmospheric pressure chemical ionization mass spectrometry","volume":"23","author":"Ma","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.chroma.2015.07.033_bib0170","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"27","author":"Titier","year":"2005","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967315010018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967315010018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:54:24Z","timestamp":1655988864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967315010018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":17,"alternative-id":["S0021967315010018"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2015.07.033","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detailed study of imatinib metabolization using high-resolution mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2015.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}